Results of Operations and Financial Condition On November 5, 2026, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2026, and providing recent corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be…

Results of Operations and Financial Condition On August 10, 2026, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026, and providing recent corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deeme…

Chief Regulatory Officer — William Turner: William Turner transitions to Special Advisor for Regulatory Affairs with Nancy Bowman, M.D., Ph.D. succeeding as Chief Regulatory Officer.

Other Events. On June 2, 2026, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing that the Company has aligned with the U.S. Food and Drug Administration on a revised, earlier ORIGIN 3 eGFR analysis plan to support the potential full approval of atacicept in adults with IgA Nephropathy. The eGFR results are now expected in the third quarter of 2026. Pending these results, the Company plans to submit a supplemental Biologics License Application for full approval of ataci…

Results of Operations and Financial Condition On May 7, 2026, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for first quarter ended March 31, 2026, and providing recent corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed…

Director — Christopher Hite: Christopher Hite was appointed to the Board of Directors and granted a stock option award.

Results of Operations and Financial Condition On February 26, 2026, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the full year ended December 31, 2025, and providing recent corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deem…

Chief Legal Officer — Jason Carter: Jason Carter will no longer serve as the Company’s Chief Legal Officer.

Other Events. Follow-On Public Offering On December 9, 2025, Vera Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering of 6,138,108 shares of the Company’s Class A common stock, par va…

Director — James R. Meyers: Mr. James R. Meyers was appointed to the Board and will serve on the Audit Committee.

Results of Operations and Financial Condition On November 5, 2025, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025, and providing recent corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be…

Entry into a Material Definitive Agreement. On August 5, 2025, Vera Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA) LLC (“TD Cowen”). Under the Sales Agreement, the Company may offer and sell, from time to time, through TD Cowen as its sales agent and/or principal, shares of its Class A common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering amount of up to $200 million (the “Shares”). The S…

Termination of a Material Definitive Agreement. The information set forth above in

Results of Operations and Financial Condition On August 5, 2025, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025, and providing recent corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. All of the information furnished in this

Entry into a Material Definitive Agreement. On June 2, 2025 (the “Effective Date”), Vera Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Agreement”) with Oxford Finance LLC, as collateral agent (in such capacity, the “Collateral Agent”), and certain lenders from time to time party thereto (collectively, the “Lenders”). The Agreement provides for term loans in an aggregate principal amount of up to $500.0 million. Under the terms of the Agreement, the Lender…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Other Events. As noted in Item 7.01, on June 2, 2025, the Company announced positive 36-week data from the Company’s ORIGIN Phase 3 clinical trial of atacicept in adult patients with IgAN. Atacicept is the Company’s potential best-in-class, disease-modifying dual inhibitor of the cytokines B-cell activating factor and a proliferation-inducing ligand. ORIGIN Phase 3 is an ongoing global, multicenter, randomized, double-blind, placebo-controlled clinical trial of 431 adults evaluating the effic…

Results of Operations and Financial Condition On May 6, 2025, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2025, and providing recent corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. All of the information furnished in this

Results of Operations and Financial Condition On February 26, 2025, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2024, and providing recent corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. All of the information furnished in this

Results of Operations and Financial Condition On November 7, 2024, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2024, and providing recent corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. All of the information furnished in this

Other Events. Follow-On Public Offering On October 29, 2024, Vera Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering of 7,142,858 shares of the Company’s Class A common stock, par va…

Other Events. As noted in Item 7.01, on October 26, 2024, the Company announced positive 96-week data from the Company’s Phase 2b ORIGIN clinical trial of atacicept in patients with IgAN. Atacicept is the Company’s potential best-in-class, disease-modifying dual inhibitor of the cytokines B-cell activating factor and a proliferation-inducing ligand. ORIGIN is a multinational, randomized, double-blind, placebo-controlled clinical trial (n=116) evaluating the efficacy and safety of atacicept in…

Results of Operations and Financial Condition. On October 28, 2024, Vera Therapeutics, Inc. (the “Company”) announced that its preliminary unaudited cash, cash equivalents and marketable securities as of September 30, 2024 were approximately $353.2 million. The Company has not yet completed its quarter-end financial close process for the quarter ended September 30, 2024. This estimate of the Company’s cash, cash equivalents and marketable securities as of September 30, 2024 is preliminary, ha…

Results of Operations and Financial Condition On August 8, 2024, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2024, and providing recent corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. All of the information furnished in this

Chief Operating Officer — David Johnson: Appointment of David Johnson as Chief Operating Officer